CRIS Current Research Information System

PEA, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.441
NA - Nord America 13.409
EU - Europa 10.521
SA - Sud America 1.276
Continente sconosciuto - Info sul continente non disponibili 913
AF - Africa 374
OC - Oceania 53
AN - Antartide 1
Totale 41.988
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.996
SG - Singapore 4.453
IT - Italia 4.354
CN - Cina 3.794
VN - Vietnam 3.015
DE - Germania 1.456
GB - Regno Unito 1.208
HK - Hong Kong 984
IN - India 903
BR - Brasile 900
SE - Svezia 747
KR - Corea 661
BD - Bangladesh 596
FR - Francia 584
NL - Olanda 514
RU - Federazione Russa 460
JP - Giappone 351
IE - Irlanda 291
FI - Finlandia 223
CA - Canada 177
AR - Argentina 143
ID - Indonesia 125
CI - Costa d'Avorio 114
UA - Ucraina 104
ES - Italia 85
MX - Messico 83
ZA - Sudafrica 82
PH - Filippine 76
AT - Austria 75
PL - Polonia 71
CH - Svizzera 70
IQ - Iraq 63
TR - Turchia 62
EC - Ecuador 60
TH - Thailandia 55
AU - Australia 47
CO - Colombia 44
TW - Taiwan 44
PK - Pakistan 42
BG - Bulgaria 40
SA - Arabia Saudita 40
SC - Seychelles 37
PA - Panama 36
CL - Cile 33
BE - Belgio 28
PE - Perù 26
PY - Paraguay 26
HR - Croazia 25
PT - Portogallo 25
JM - Giamaica 24
JO - Giordania 24
RO - Romania 24
GR - Grecia 22
UZ - Uzbekistan 22
VE - Venezuela 22
CR - Costa Rica 21
EE - Estonia 19
EG - Egitto 17
MA - Marocco 17
IL - Israele 16
MY - Malesia 16
NG - Nigeria 16
TN - Tunisia 15
CZ - Repubblica Ceca 14
IR - Iran 13
AE - Emirati Arabi Uniti 12
KE - Kenya 12
LT - Lituania 12
TG - Togo 12
UY - Uruguay 12
DO - Repubblica Dominicana 10
HU - Ungheria 10
NP - Nepal 10
SK - Slovacchia (Repubblica Slovacca) 10
AZ - Azerbaigian 9
HN - Honduras 9
DZ - Algeria 8
GT - Guatemala 7
LV - Lettonia 7
OM - Oman 7
PR - Porto Rico 7
TT - Trinidad e Tobago 7
BO - Bolivia 6
CY - Cipro 6
ET - Etiopia 6
LB - Libano 6
RS - Serbia 6
UG - Uganda 6
GA - Gabon 5
MD - Moldavia 5
NI - Nicaragua 5
SV - El Salvador 5
DK - Danimarca 4
IS - Islanda 4
KG - Kirghizistan 4
MN - Mongolia 4
NO - Norvegia 4
QA - Qatar 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
Totale 40.977
Salva come PNG Salva come JPEG
Città #
Singapore 3.066
San Jose 1.392
Ashburn 1.324
Hefei 1.298
Southend 952
Hong Kong 927
Fairfield 814
Ho Chi Minh City 747
Santa Clara 653
Dallas 646
Seoul 621
Hanoi 552
Bologna 549
Princeton 477
Council Bluffs 438
Boardman 435
Milan 426
Beijing 412
Woodbridge 411
Lauterbourg 388
Seattle 356
Dong Ket 354
Houston 346
Rome 307
Los Angeles 301
Cambridge 300
Tokyo 296
Wilmington 294
Dublin 287
New York 274
Chandler 245
Ann Arbor 186
Des Moines 160
Buffalo 157
Redondo Beach 135
Bengaluru 132
Helsinki 125
Chicago 124
Da Nang 117
Abidjan 113
Redwood City 105
Naples 102
Haiphong 96
São Paulo 91
Shanghai 89
Turin 87
Florence 83
Frankfurt am Main 76
Jakarta 70
Lappeenranta 66
Genoa 65
San Diego 65
Berlin 62
Phoenix 60
London 56
Nuremberg 56
The Dalles 56
Guangzhou 55
Amsterdam 52
Nanjing 52
Munich 51
Redmond 51
San Francisco 51
Verona 49
Castel Maggiore 48
Toronto 45
Atlanta 44
Hangzhou 44
Modena 44
Tongling 44
Bremen 43
Medford 43
Jinan 42
Vienna 42
Bari 40
Warsaw 40
Mumbai 38
Denver 37
Montreal 37
Paris 37
Orem 36
Bern 35
Mexico City 35
Sofia 35
Hải Dương 34
Biên Hòa 33
Padua 33
Can Tho 32
Trieste 32
Baghdad 31
Istanbul 31
Padova 30
Palermo 30
Brooklyn 28
Falkenstein 28
Saint Petersburg 28
Turku 28
Johannesburg 27
Salt Lake City 27
Vicenza 27
Totale 24.071
Salva come PNG Salva come JPEG
Nome #
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: One stone for two birds? 1.183
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 380
Oral gabapentin disposition in patients with epilepsy after a high- protein meal 344
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 330
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 319
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 269
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel 264
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 254
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 250
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 238
Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin? 235
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 231
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 231
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 228
[PK/PD profile and post-marketing surveillance of levofloxacin] 226
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 222
Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales 219
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 215
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 211
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 207
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 206
Enhancement of in-vitro activity of ofloxacin and gentamicin by rat serum 205
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 205
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 202
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 202
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 198
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data 198
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis 197
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 192
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 191
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 190
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 190
Methicillin-resistant Staphylococcus epidermidis knee prosthetic infection treatment with two-stage revision and fosfomycin–rifampin combination therapy: a case report 188
Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis 186
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 185
Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales 184
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 183
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 183
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections? 182
Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. 182
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 181
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 180
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 180
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 177
Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections 177
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 177
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 177
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 173
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 173
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 173
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. 172
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 171
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 170
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid 170
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 170
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 168
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# 166
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 165
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. 165
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 164
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 161
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice 157
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 157
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 157
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 157
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 154
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections 154
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 154
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring 153
Accurate and Sensitive UHPLC–Tandem Mass Spectrometry Sequential Methods for Therapeutic Drug Monitoring of Aztreonam/Avibactam in Human Plasma 152
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 152
Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia? 151
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 150
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 150
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 149
Blood concentrations and clinical effect of cyclosporin in psoriasis 149
Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections 148
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 148
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 148
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 148
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM) 146
The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts 146
Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia 145
Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions 145
A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 145
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 144
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 144
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia 142
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 142
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 141
Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia 139
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 139
Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT 139
Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion 138
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients 138
Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action 137
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 137
β-blockers and diltiazem combination—bear in mind the risk of heart block 137
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases 136
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients 135
Totale 19.218
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.529
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.529
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.376 0 51 221 215 623 321 112 289 327 163 460 594
2022/20232.836 354 309 161 431 155 184 173 157 489 92 180 151
2023/20242.003 99 171 129 207 178 204 204 180 135 207 160 129
2024/20257.972 275 1.026 744 590 991 404 690 246 170 756 655 1.425
2025/202619.303 1.339 2.328 2.140 1.682 1.373 843 2.207 994 3.020 1.277 1.201 899
2026/20272.001 1.027 974 0 0 0 0 0 0 0 0 0 0
Totale 41.988